Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model

  • Cancer Discov. 2025 Jan 13;15(1):162-178. doi: 10.1158/2159-8290.CD-24-0489.
Yonghong Liu  1 ,  Jincheng Han  1 ,  Wen-Hao Hsu  1 ,  Kyle A LaBella  1 ,  Pingna Deng  1 ,  Xiaoying Shang  1 ,  Paulino Tallón de Lara  1 ,  Li Cai  1 ,  Shan Jiang  1 ,  Ronald A DePinho  1
Affiliations
  • 1. Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
PMID: 39348506 DOI: 10.1158/2159-8290.CD-24-0489
Abstract

Clinically available KRAS* inhibitors and IO agents alleviated the immunosuppressive tumor microenvironment in PDAC. Profound tumor regression and prolonged survival in an autochthonous PDAC model provide a compelling rationale for combining KRAS* inhibition with IO agents targeting multiple arms of the immunity cycle to combat PDAC.

Products